Australis Capital Invests in Folium Biosciences a Global Leader in Non-Psychoactive Cannabinoid Production

This information was provided by prnewswire

Send your Press Release here.

LAS VEGAS, Jan. 14, 2019 /CNW/ – Australis Capital Inc. (CSE: AUSA) (“Australis” or the “Company“) is pleased to announce the Company has invested $3,000,000 USD in Folium Biosciences (“Folium“), the largest vertically integrated producer, manufacturer, and distributor of hemp derived phytocannabinoids in the United States. Folium also owns and operates the largest phytocannabinoid extraction and purification facility in the United States, with plans for a new pharmaceutical division and the completion of their Canadian facility in 2019.

“With the passing of the 2018 Farm Bill and the floodgates opening for this vibrant and exciting industry, we are poised for strong growth this year,” said Kashif Shan, CEO of Folium. “As a global industry leader and authority in PCR hemp oil extraction and product development, we welcome Australis’ participation in this private placement as we continue to pave the way and dominate the marketplace.”

Supplying the market with its own unique 0.0% THC phytocannabinoid-rich hemp oil, Folium is a global leader in non-psychoactive cannabinoids. Folium’s chromatographic purification process selectively removes the psychoactive component from the phytocannabinoid-rich hemp oil. Folium is certified by the Colorado Department of Public Health and Environment as a producer of 0.0% THC products, including CBD hemp oil, CBD gel caps, water soluble CBD, Cannabidiol HYDROPCR, CBD e-liquid, CBD concentrates, CBD for pets, CBD salves and balms, CBD tinctures, CBD face masks, and white-label CBD products.

“Our strategic investment in Folium Biosciences provides Australis and our brands access to the leading player in the fast-evolving United States CBD market,” said Scott Dowty, CEO of Australis. “Folium’s breadth of expertise, spanning production, extraction, branding and commercialization, will greatly benefit Australis as we introduce and expand our CBD product offerings in the United States in the months and years ahead.”